Miller Lisa K sold $520K of LFST

Miller Lisa K (Chief Operating Officer) sold 47,912 shares of LifeStance Health Group, Inc. (LFST) at $10.85 ($0.52M total) on 2026-08-10 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · Miller Lisa K
Published Aug 12, 2026, 8:59 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Aug 12, 2026, 9:13 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$LFST
Neutral
high confidence
Mentioned
$LFST
Relevance
4/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$LFSTNeutralLow
01

Why it matters

An insider sale by the COO is disclosed with transaction size, price, and confirmation of a pre-arranged 10b5-1 plan, which generally limits interpretive impact.

02

Market read

Traders may treat this as routine insider activity unless paired with other fundamental or guidance catalysts.

03

What to watch

The article provides no context on total insider holdings changes beyond the post-transaction figure, and does not indicate whether other insiders sold or bought around the same time.

Relevance 4/10Novelty 3/10Timing: filed 2026-08-12, transaction dated 2026-08-10

Background

The article is a SEC Form 4 insider transaction disclosure for LifeStance Health Group, Inc.

Company-level read

Ticker impact

$LFSTNeutralHigh confidence
Context

LifeStance COO Lisa K Miller sold 47,912 shares in an open-market transaction for about $519,845 under a 10b5-1 plan.

Expected impact

Low likelihood of a sustained price move solely from this Form 4 sale; any reaction is likely muted.

Evidence & confidence

Form 4 details a single insider open-market sale with stated 10b5-1 pre-arrangement, which typically reduces interpretive value versus discretionary selling.

Market effects

No sector-level implications disclosed; this is company-specific insider transaction reporting.

None indicated.

None indicated.

Counterpoint

Even with a 10b5-1 plan, repeated insider selling can coincide with internal caution, so traders may still watch for follow-on disclosures.

Key entities

  • LifeStance Health Group, Inc.

    Subject of the Form 4 insider transaction disclosure.

  • Lisa K Miller

    Chief Operating Officer who sold shares in an open-market transaction.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$LFSTMed

BMO raises Lifestance Health stock price target on strong results

BMO Capital raised its price target on Lifestance Health (LFST) to $16.00, citing strong Q3 results. Revenue beat estimates by 5.6%, and EBITDA exceeded by 23.6%. The company raised its full-year outlook, but expects a sequential EBITDA decline due to reinvestment. LFST trades at $13.43 with a $5.1B market cap. The company also announced Q3 2026 earnings, surpassing expectations with a 25% revenue increase.

$LFSTMed

What LifeStance Health Group (LFST) Said on Its Q3 Earnings Call

LifeStance Health Group (LFST) forecasted Q4 revenue of $446M-$466M and adjusted EBITDA of $56M-$64M. The company expects a 1-2% reduction in 2027 revenue growth due to a new electronic health record system. LifeStance expanded specialty services, including TMS and SPRAVATO, and plans to continue acquisitions and center openings. Management expects specialty services revenue to reach $70M this year, up from $50M in 2025.

$LFSTMed

LifeStance Health Group Inc (LFST) (Q3 2026) Earnings Call Highlights: Revenue Jumps 25%

LifeStance Health (LFST) reported 25% revenue growth in Q3 2026. The company expects EHR implementation to reduce 2027 revenue growth by 1-2% and cost $20-30M. Clinician retention is stable, but new clinician retention is low. Q4 adjusted EBITDA guidance suggests a sequential decline due to planned investments. Specialty services, including Spravato, are growing but face variable payer reimbursement. Management remains optimistic about long-term margin expansion and clinician growth.

$LFSTHighAI 8/10

LifeStance (LFST) Q3 2026 Earnings Call Transcript

LifeStance (LFST) reported Q3 2026 revenue growth of 25% to $456M, driven by increased visit volumes and higher revenue per visit. The company expanded its clinician base by 11% and opened 8 new centers. It also raised full-year revenue guidance to $1.741B-$1.761B. LifeStance highlighted strong results in specialty services for treatment-resistant depression and plans to invest in strategic priorities. The company expects temporary revenue growth impact in 2027 due to EHR implementation.

$LFSTMed

LifeStance Health: Q3 Earnings Snapshot

LifeStance Health Group Inc. (LFST) reported Q3 net income of $22.4M, or 6 cents per share, beating estimates. Revenue was $455.9M, also exceeding forecasts. The company expects Q4 revenue of $446M-$466M and full-year revenue of $1.74B-$1.76B.